Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, People's Republic of China.
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, 510060, People's Republic of China.
J Hematol Oncol. 2021 Feb 12;14(1):24. doi: 10.1186/s13045-021-01037-x.
Mesenchymal stromal cells (MSCs), also known as mesenchymal stem cells, have been intensely investigated for clinical applications within the last decades. However, the majority of registered clinical trials applying MSC therapy for diverse human diseases have fallen short of expectations, despite the encouraging pre-clinical outcomes in varied animal disease models. This can be attributable to inconsistent criteria for MSCs identity across studies and their inherited heterogeneity. Nowadays, with the emergence of advanced biological techniques and substantial improvements in bio-engineered materials, strategies have been developed to overcome clinical challenges in MSC application. Here in this review, we will discuss the major challenges of MSC therapies in clinical application, the factors impacting the diversity of MSCs, the potential approaches that modify MSC products with the highest therapeutic potential, and finally the usage of MSCs for COVID-19 pandemic disease.
间充质基质细胞（MSCs），也称为间充质干细胞，在过去几十年中，已被广泛研究用于临床应用。然而，尽管在各种动物疾病模型中取得了令人鼓舞的临床前结果，但大多数注册的临床试验应用 MSC 疗法治疗各种人类疾病都未能达到预期效果。这可能归因于研究之间 MSC 身份的标准不一致及其固有的异质性。如今，随着先进的生物学技术的出现和生物工程材料的实质性改进，已经开发出了一些策略来克服 MSC 应用中的临床挑战。在这篇综述中，我们将讨论 MSC 疗法在临床应用中面临的主要挑战、影响 MSCs 多样性的因素、能够最大程度发挥 MSC 治疗潜力的 MSC 产品的潜在修饰方法，以及 MSCs 在 COVID-19 大流行疾病中的应用。
